Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that Pfizer Inc. has initiated a Phase 1 clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, a selective and potent motilin receptor agonist being developed for the treatment of gastroesophageal reflux disease (GERD) and potentially other gastrointestinal (GI) disorders. The Phase 1 clinical trial is designed to test the safety, tolerability and pharmacokinetics of PF-04548043 in healthy subjects. In December 2006, Kosan and Pfizer established a worldwide license agreement for Kosan's motilin agonist program, including KOS-2187 and related compounds, in a transaction potentially valued at $250 million for the successful development and commercialization of PF-04548043 for one indication as well as royalties on worldwide sales.

"Kosan today has four advancing clinical programs, underscoring the increasing value of our development pipeline," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Consistent with Kosan's focus on oncology, we successfully out-licensed KOS-2187 and our motilin receptor agonist program to Pfizer, a company with a strong gastrointestinal capability that could best exploit its therapeutic and commercial potential. We appreciate Pfizer's commitment to the development and potential commercialization of this promising prokinetic compound and look forward to its rapid advancement through the clinic."

About PF-04548043 and Motilin Receptor Agonists

Motilin, a hormone secreted by the small intestine, stimulates gastrointestinal motility (movement). The activity of motilin is mediated through the G-protein coupled
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Inferior Vena Cava (IVC) Filters ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sector is projected to reach US$435 million by 2016. ... nearly 39% (2015) of the global value while ...
(Date:12/15/2014)... Norway , December 15, 2014 ... innovative drugs for aggressive drug resistant cancers, today announces ... in a private placing from new and existing investors. ... financing to support the development of its pipeline of ... program for its lead drug candidate, BGB324, a first-in-class ...
(Date:12/15/2014)... Dec. 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... been added to the NASDAQ Biotechnology Index (NBI). ... become effective upon market open on December 22, ... designed to track the performance of a set ... biotechnology or pharmaceutical according to the Industry Classification ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... Jan. 18, 2011 Rochester Medical Corporation (Nasdaq: ... markets close on Tuesday, January 25, 2011.  The Company ... its earnings report.  The Company also plans to discuss ... 12, 2011.  The call will begin at 3:30 p.m. ...
... 18, 2011 Fenwal, Inc. of Lake Zurich, Illinois, ... signed an agreement under which Fenwal will co-market and ... plasma centers and hospitals in the United States and ... Genesis™ blood collection mixers and monitors, RapidSeal II™ tube ...
Cached Medicine Technology:Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011 2Fenwal, GenesisBPS Enter Agreement for Blood-Specialty Products 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... plan of enforcing a ban on smoking in enclosed public ... such other public places will come under the purview of ... private homes. ,All pubs and restaurants in England ... in their location from July 1st, 2007. According to Health ...
... Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic ... to a study// led by researchers at the San Francisco ... all, and there were several adverse side effects,” says lead ... program at SFVAMC. “People with symptoms of PTSD should probably ...
... an eating disorder - monitoring meals, friends and activities - ... researchers at the Stanford University School of Medicine// and Lucile ... two key areas: Internet use among adolescents with the condition, ... ,One study, to be published in the December issue of ...
... treated mainly elderly patients for health problems such as ... patients who have the same ailments. ,A ... focuses on the increasing prevalence of metabolic syndrome, a ... high blood pressure and abnormal levels of glucose (sugar) ...
... undertake a long-term weight training program produce more ... physiologists //to understand why weight training improves muscle ... study published in the December issue of the ... different forms of growth hormone, used different testing ...
... neo-natal care find recordings of consultations with their consultants ... requiring care in neo-natal intensive care units (NICU) often ... in Australia set out to assess the usefulness of ... consultants. Two hundred mothers with babies in NICU were ...
Cached Medicine News:Health News:Common PTSD Drug is No More Effective Than Placebo 2Health News:Study Focus on the Need for Vigilance in Two Key Areas Among Adolescents 2Health News:Study Focus on the Need for Vigilance in Two Key Areas Among Adolescents 3Health News:Treating Obesity Vital for Public Health, Physicians Say 2Health News:Varying Weight Training Intensity Ups Growth Hormone in Women 2
... Advanced Technologies, The UroMax Ultra ia ... of high pressure and low profile., ... yields a remarkably strong material that ... balloon materials., Non-Compliant Balloons, A compliant ...
... Fr Straight Channel; 33 or 42 cm ... Operating Ureteroscopes offer a small distal diameter ... to the ureter for diagnosis and treatment. ... ideal for large operating instruments, mechanical (Lithoclast) ...
... Small 6.9 Fr Diameter with Two ... ,MICRO-6L Long Semi-Rigid Ureteroscope, with a longer ... ureteroscope with two large working channels for ... allow you to basket a stone and ...
... The ACMI USA Series DUR-8 Durable Flexible ... the entire intrarenal collecting system with little ... superior secondary deflection allow complete intrarenal access, ... facilitates access to the proximal ureter and ...
Medicine Products: